Amylin Articles
AstraZeneca and Bristol-Myers complete diabetes alliance expansion; Lilly revises guidance
10 August 2012
Amylin seduced by $5.3 billion bid from Bristol-Myers; AstraZeneca chips in for share of the action
2 July 2012
Amylin operating loss leaps to over $30 million
27 April 2012
EMA advisory backs Humira for UC and expanded use of Byetta
20 February 2012
Amylin 4th-qtr loss widens on charges
7 February 2012
FDA finally approves Bydureon
30 January 2012
Amylin diabetes drug exenatide deal with Eli Lilly terminated, with $1.45 billion settlement to Lilly
9 November 2011
Amylin and Lilly’s diabetes drug Byetta has rapid, powerful anti-inflammatory effect
4 November 2011
Strong new data on Novo Nordisk’s Victoza and Lilly/Amylin’s Bydureon presented at EADS
13 September 2011
US FDA sets PDUFA action dates for Bydureon and peginesatide
12 August 2011
Amylin and Takeda drop combo obesity drug development
8 August 2011
Amylin and Lilly to re-file Bydureon with US FDA sooner than expected with new tQT data
11 July 2011
Alkermes shrugs off Bydureon and focuses on pipeline, company reveals in interview with EP Vantage
15 November 2010
Amylin’s diabetes drug Bydureon approval delayed again by US FDA call for more clinical data; 3rd qtr sales data
20 October 2010
US FDA exec questions safety of Lilly and Amylin’s Byetta, saying it may pose cancer risk
12 April 2010
Amylin and partner Takeda move obesity drug candidate into Ph III
25 February 2010
US FDA warns four drugmakers on inaccurate promotion
13 January 2010
Roche/Ipsen’s taspoglutide meets Ph III primary endpoints against Lantus and placebo in patients with high BMI
18 December 2009
US FDA revises Byetta label to reflect possible kidney problems
3 November 2009
Ipsen launch’s Dysport in USA, updates on taspoglutide
29 October 2009
TWST releases biotech investment report
9 June 2009
Novo Nordisk
7 May 2009
Exenatide once weekly NDA submitted to FDA
6 May 2009
Icahn pushing Lilly to buy Amylin?
21 April 2009
Diabetes sales weaken with economy
20 April 2009
Amylin narrows 1st-qtr loss 34% to $47M
20 April 2009
Stock Commentary - New York week to Aug 15
8 April 2009
Altea in Lilly/Amylin deal for diabetes patch
7 April 2009
Amylin up 8% as Byetta cleared of CV health risk
27 March 2009
Stock Commentary - New York week to Mar 16, 2009
23 March 2009
Stock Commentary - New York week to Mar 2, 2009
9 March 2009
Stock Commentary - New York week to Feb 23, 2009
2 March 2009
Stock Commentary - New York week to Feb 9, 2009
16 February 2009
Amylin's loss deeper on Byetta worries
9 February 2009
Stock Commentary - New York week to Jan 19, 2009
26 January 2009
Leptin sensitizers lead to weight loss in mice
26 January 2009
Stock Commentary - New York week to Jan 5, 2009
12 January 2009
Stock Commentary - New York week to Dec 15, 2008
22 December 2008
Lilly expects to report loss for full-year 2008 but 2009 guidance unaffected by forex
22 December 2008
Stock Commentary - New York week to Dec 8, 2008
15 December 2008
FDA review of wider Byetta label delayed
15 December 2008
Stock Commentary - New York week to Dec 1, 2008
8 December 2008
Stock Commentary - New York week to Nov 17, 2008
24 November 2008
BioSeek licenses peptides from Amylin
24 November 2008
Stock Commentary - New York week to Nov 10, 2008
17 November 2008
Amylin shares plunge 26% on possible Byetta LAR US approval delay
10 November 2008
Stock Commentary - New York week to Nov 3, 2008
10 November 2008
Stock Commentary - New York week to Oct 27, 2008
3 November 2008
Amylin hits 6-year low on Byetta LAR concerns
3 November 2008
Amylin and Lilly enter supply agreement for Byetta once weekly
27 October 2008
Stock Commentary - New York week to Oct 20, 2008
27 October 2008
Novo's liraglutide achieves greater glycemic control than Amylin/Lilly's Byetta in LEAD 6
27 October 2008
Amylin to present obesity pipeline data
13 October 2008
Carl Icahn increases stake in Amylin to 7.3%, shares jump 4.7%
22 September 2008
Drug equivalent to gastric bypass in 5 years, says UK's UCL
15 September 2008
Byetta: better post-meal glucose reduction than Januvia
15 September 2008
Liraglutide improves multiple endpoints in LEAD-4
15 September 2008
Stock Commentary - New York week to Sept 1, 2008
8 September 2008
Stock Commentary - New York week to Aug 25, 2008
1 September 2008
UPDATE: FDA considering strong warning on Byetta; potential fall-out for all GLP-1s
1 September 2008
Amylin's 2nd-qtr 2008 loss widens to $64.8M
4 August 2008
Stock Commentary - New York week to June 16, 2008
23 June 2008
Stock Commentary - New York week to June 9, 2008
16 June 2008
Liraglutide superior to Byetta: LEAD study
16 June 2008
Amylin/Lilly's Byetta achieves glycemic control
16 June 2008
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
